The global semi-solid dosage contract manufacturing market size was valued at USD 17.57 billion in 2023 and is projected to grow at a CAGR of 11.12% from 2024 to 2030. The rising demand for patient-friendly medications coupled with growing prevalence of chronic diseases such as skin diseases, arthritis, and pain management aids the market growth. Moreover, there is a growing demand for manufacturing outsourcing due to its cost-effectiveness. Furthermore, regulatory compliance and quality assurance, technological advancements including innovation in formulation technologies, are likely to boost their demand over the forecast period.
The high prevalence of chronic conditions such as skin diseases, arthritis and the requirement for pain management solutions due to the ageing population around the world is a major factor for the market growth. With an estimated 1.8 billion people affected by over 3,000 types of skin conditions at any given time, according to the World Health Organization, there's a massive demand for effective treatments. The U.S. population is experiencing a significant shift towards aging. According to the January 2024 fact sheet by the Population Reference Bureau, the number of Americans aged 65 and older is expected to surge from 58 million in 2022 to 82 million by 2050, representing a substantial 47% increase. Additionally, the proportion of the total population comprised of individuals aged 65 and older is projected to rise from 17% to 23%, marking the oldest age distribution in U.S. history.
In addition, according to the Global Burden of Disease Study 2021, skin diseases rank as the eighth leading cause of global health burden. Semi-solid dosage forms, such as creams and ointments, are a preferred method of administration for many skin diseases, offering a convenient and mess-free application. This surge in demand for skin condition and pain management treatments is propelling the growth of the market, as pharmaceutical companies seek out partners with the expertise to produce these medications efficiently and in large quantities. Further, according to the CDC report covering the period from 2019 to 2021, arthritis was most prevalent in 17.9% of men and 24.2% of women in the U.S. (NHIS).
Additionally, contract manufacturing enables pharmaceutical companies to access manufacturing capabilities, adhere to regulatory standards, and support to minimize costs associated with in-house production facilities. Strategic collaborations between pharmaceutical companies and contract manufacturers are instrumental in the efficient production of semi solid dosage forms, facilitating faster market entry for drugs further optimization of existing formulations. Setting up and maintaining in-house production lines for semi-solid medications requires substantial investments. This includes specialized equipment for mixing, filling, and packaging these dosage forms, as well as the expertise to operate them efficiently. By partnering with a contract manufacturer (CMO), pharmaceutical companies can bypass these upfront costs and ongoing maintenance expenses. CMOs specialize in semi-solid production and have economies of scale, allowing them to leverage their expertise and equipment for multiple clients.
The semi-solid dosage contract manufacturing market is witnessing a surge of innovative developments, driven by advancements in formulation technology and a growing focus on patient-centric solutions. Formulation innovations include the use of nano and micronized particles to enhance bioavailability, as well as sophisticated particle size distribution techniques to optimize stability and performance. Manufacturers are also prioritizing patient compliance, with the introduction of user-friendly packaging designs and self-administration features. Strategic collaborations between pharmaceutical companies and contract manufacturers are enabling efficient production and faster market entry of these specialized formulations.
While the market is primarily driven by the growing demand for pharmaceutical creams, ointments, and gels, CMOs can leverage their expertise in these semi-solid dosage forms to cater to the cosmetics industry as well. This allows them to expand their client base and optimize production lines. Furthermore, the growing consumer interest in topical skincare products creates additional opportunities for CMOs to partner with cosmetic companies in developing and manufacturing innovative creams, serums, and lotions. This synergy between the pharmaceutical and cosmetic sector helps to fuel the overall growth of the market.
Furthermore, the demand for personalized medicine is fueling the development of customized semi-solid dosage forms tailored to individual needs. Absorption-enhancing ingredients and novel excipients are also being leveraged to improve the efficacy and bioavailability of these topical treatments. These multifaceted innovations are transforming the semi-solid dosage form market, offering more effective, convenient, and personalized solutions for a wide range of skin, eye, and chronic pain conditions.
This product will be delivered within 1-3 business days.
The high prevalence of chronic conditions such as skin diseases, arthritis and the requirement for pain management solutions due to the ageing population around the world is a major factor for the market growth. With an estimated 1.8 billion people affected by over 3,000 types of skin conditions at any given time, according to the World Health Organization, there's a massive demand for effective treatments. The U.S. population is experiencing a significant shift towards aging. According to the January 2024 fact sheet by the Population Reference Bureau, the number of Americans aged 65 and older is expected to surge from 58 million in 2022 to 82 million by 2050, representing a substantial 47% increase. Additionally, the proportion of the total population comprised of individuals aged 65 and older is projected to rise from 17% to 23%, marking the oldest age distribution in U.S. history.
In addition, according to the Global Burden of Disease Study 2021, skin diseases rank as the eighth leading cause of global health burden. Semi-solid dosage forms, such as creams and ointments, are a preferred method of administration for many skin diseases, offering a convenient and mess-free application. This surge in demand for skin condition and pain management treatments is propelling the growth of the market, as pharmaceutical companies seek out partners with the expertise to produce these medications efficiently and in large quantities. Further, according to the CDC report covering the period from 2019 to 2021, arthritis was most prevalent in 17.9% of men and 24.2% of women in the U.S. (NHIS).
Additionally, contract manufacturing enables pharmaceutical companies to access manufacturing capabilities, adhere to regulatory standards, and support to minimize costs associated with in-house production facilities. Strategic collaborations between pharmaceutical companies and contract manufacturers are instrumental in the efficient production of semi solid dosage forms, facilitating faster market entry for drugs further optimization of existing formulations. Setting up and maintaining in-house production lines for semi-solid medications requires substantial investments. This includes specialized equipment for mixing, filling, and packaging these dosage forms, as well as the expertise to operate them efficiently. By partnering with a contract manufacturer (CMO), pharmaceutical companies can bypass these upfront costs and ongoing maintenance expenses. CMOs specialize in semi-solid production and have economies of scale, allowing them to leverage their expertise and equipment for multiple clients.
The semi-solid dosage contract manufacturing market is witnessing a surge of innovative developments, driven by advancements in formulation technology and a growing focus on patient-centric solutions. Formulation innovations include the use of nano and micronized particles to enhance bioavailability, as well as sophisticated particle size distribution techniques to optimize stability and performance. Manufacturers are also prioritizing patient compliance, with the introduction of user-friendly packaging designs and self-administration features. Strategic collaborations between pharmaceutical companies and contract manufacturers are enabling efficient production and faster market entry of these specialized formulations.
While the market is primarily driven by the growing demand for pharmaceutical creams, ointments, and gels, CMOs can leverage their expertise in these semi-solid dosage forms to cater to the cosmetics industry as well. This allows them to expand their client base and optimize production lines. Furthermore, the growing consumer interest in topical skincare products creates additional opportunities for CMOs to partner with cosmetic companies in developing and manufacturing innovative creams, serums, and lotions. This synergy between the pharmaceutical and cosmetic sector helps to fuel the overall growth of the market.
Furthermore, the demand for personalized medicine is fueling the development of customized semi-solid dosage forms tailored to individual needs. Absorption-enhancing ingredients and novel excipients are also being leveraged to improve the efficacy and bioavailability of these topical treatments. These multifaceted innovations are transforming the semi-solid dosage form market, offering more effective, convenient, and personalized solutions for a wide range of skin, eye, and chronic pain conditions.
Global Semi-solid Dosage Contract Manufacturing Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the publisher has segmented the global semi-solid dosage contract manufacturing market report on the basis of type, product, end use, company size and region:- Type Outlook (Revenue, USD Million, 2018 - 2030)
- Topical
- Transdermal
- Oral
- Product Outlook (Revenue, USD Million, 2018 - 2030)
- Creams
- Ointments
- Gels
- Lotions
- Pastes
- Others
- End Use Outlook (Revenue, USD Million, 2018 - 2030)
- Pharmaceutical Companies
- Cosmeceutical Companies
- Others
- Company Size Outlook (Revenue, USD Million, 2018 - 2030)
- Large Size Companies
- Medium & Small Size Companies
- Others
- Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Semi-solid Dosage Contract Manufacturing Market Variables, Trends & Scope
Chapter 4. Semi-solid Dosage Contract Manufacturing Market: Type Estimates & Trend Analysis
Chapter 5. Semi-solid Dosage Contract Manufacturing Market: Product Estimates & Trend Analysis
Chapter 6. Semi-solid Dosage Contract Manufacturing Market: End Use Estimates & Trend Analysis
Chapter 7. Semi-solid Dosage Contract Manufacturing Market: Company Size Estimates & Trend Analysis
Chapter 8. Semi-solid Dosage Contract Manufacturing Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Lonza Group Ltd.
- Lubrizol Life Science
- Cambrex Corporation
- Contract Pharmaceuticals Limited
- Bora Pharmaceutical CDMO
- Ascendia Pharmaceuticals
- Pierre Fabre group
- Piramal Pharma Solutions
- DPT Laboratories, LTD
- MedPharm Ltd
- Catalent, Inc.
- Recipharm AB
- Aenova Group
- Almac Group
- Ajinomoto Bio-Pharma Services
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 17.57 Billion |
| Forecasted Market Value ( USD | $ 36.58 Billion |
| Compound Annual Growth Rate | 11.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
